monotherapy

1:22
CLL12: ibrutinib monotherapy upfront, a potential competitor for ‘watch-and-wait’?
Michael Hallek
3:30
Current affairs: opinion on quizartinib approval status in AML
Mark Levis
3:56
RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML
Richard Thomas Maziarz
1:31
Duvelisib after progression on ofatumumab in R/R CLL: DUO crossover extension study
Matthew Davids
2:08
7-year follow-up of ibrutinib monotherapy for R/R and first-line CLL
Susan O’Brien
2:25
Beat AML: promising results with enasidenib for AML in the frontline
Eytan Stein
4:15
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
0:55
Long-term follow-up of acalabrutinib in R/R mantle cell lymphoma
Simon Rule
2:58
A big year for CLL: ibrutinib updates from ASH
William Wierda
2:35
Stapled peptide ALRN-6924 for AML and MDS
David Sallman
1:13
Achieving longer remissions with venetoclax monotherapy in R/R CLL
William Wierda
2:02
Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy
Carsten Niemann
0:48
DUO results: duvelisib or ofatumumab monotherapy for R/R CLL?
Stephan Stilgenbauer
2:04
A novel mechanism of action for daratumumab in myeloma
Niels van de Donk
1:46
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
Niels van de Donk
2:49
Daratumumab in myeloma update: expanding indications
Niels van de Donk
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals